Approval · Notice of Compliance 1639 · 2004
PHOSLO TABLETS: Notice of Compliance 1639
Issued April 20, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1639
- Date
- April 20, 2004
- Company
- Nabi Biopharmaceuticals
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Phosphate binder
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PHOSLO TABLETS | 02229437 | Cancelled Post Market |
Medicinal ingredients
- CALCIUM ACETATE 667 MG per TAB